Spencer Fisk appointed Senior VP Of Manufacturing for Rubius Therapeutics

Rubius Therapeutics asserted the appointment of Spencer Fisk as Senior Vice-President, Manufacturing. Rubius Therapeutics is a biotechnology company endeavoring the creation of a new class of active, ready-to use and life-changing cellular therapies. Mr. Frisk brings on board thirty years of experience in pharmaceutical and biotechnology experience.

Torben Straight Nissen, Ph.D., President of Rubius Therapeutics said “Spencer’s expertise and decades of experience in process development and manufacturing will be invaluable. I look forward to working closely together as we continue to deliver on the promise of the next generation of cellular therapeutics for patients in need.”

Mr. Fisk spent the last six years at Novartis, where he most recently led the CMC development and manufacturing organization to deliver the CAR-T portfolio for the company, and successfully registered and launched Kymriah .He was also a key driver in the registration of Cosentyx and supported the registration and approval of Erelzi and Rixathon. Prior to Novartis, Mr. Fisk held leadership positions in the areas of Manufacturing and Process Development at Merck and Schering Plough.